142 related articles for article (PubMed ID: 26708191)
1. An Informed and Activated Patient: Addressing Barriers in the Pathway From Education to Outcomes.
Wright Nunes JA; Cavanaugh KL; Fagerlin A
Am J Kidney Dis; 2016 Jan; 67(1):1-4. PubMed ID: 26708191
[No Abstract] [Full Text] [Related]
2. Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD.
Morton RL; Schlackow I; Staplin N; Gray A; Cass A; Haynes R; Emberson J; Herrington W; Landray MJ; Baigent C; Mihaylova B;
Am J Kidney Dis; 2016 Jan; 67(1):31-9. PubMed ID: 26385817
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP).
Mihaylova B; Schlackow I; Herrington W; Lozano-Kühne J; Kent S; Emberson J; Reith C; Haynes R; Cass A; Craig J; Gray A; Collins R; Landray MJ; Baigent C;
Am J Kidney Dis; 2016 Apr; 67(4):576-84. PubMed ID: 26597925
[TBL] [Abstract][Full Text] [Related]
4. Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT".
Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White J; Tershakovec AM; Blazing MA; Braunwald E
Circulation; 2016 Mar; 133(13):e463. PubMed ID: 27022050
[No Abstract] [Full Text] [Related]
5. SPG5 siblings with different phenotypes showing reduction of 27-hydroxycholesterol after simvastatin-ezetimibe treatment.
Mignarri A; Carecchio M; Del Puppo M; Magistrelli L; Di Bella D; Monti L; Dotti MT
J Neurol Sci; 2017 Dec; 383():39-41. PubMed ID: 29246618
[No Abstract] [Full Text] [Related]
6. Can Clinicians Improve on the Effectiveness of Statins with Additional Lipid-lowering Therapies?
Frishman WH
Am J Med; 2015 Nov; 128(11):1160-1. PubMed ID: 26184685
[No Abstract] [Full Text] [Related]
7. [Letter].
Poli A
G Ital Cardiol (Rome); 2015 Dec; 16(12):739-40. PubMed ID: 26667952
[No Abstract] [Full Text] [Related]
8. [The IMPROVE-IT trial].
Menozzi A; Lina D; Urbinati S; Greco C
G Ital Cardiol (Rome); 2015 Dec; 16(12):667-71. PubMed ID: 26667942
[No Abstract] [Full Text] [Related]
9. Bringing back targets to "IMPROVE" atherosclerotic cardiovascular disease outcomes: the duel for dual goals; are two targets better than one?
Michos ED; Martin SS; Blumenthal RS
Circulation; 2015 Sep; 132(13):1218-20. PubMed ID: 26330413
[No Abstract] [Full Text] [Related]
10. Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older.
Weingärtner O; Sijbrands EJG; Lütjohann D
JAMA Cardiol; 2020 Feb; 5(2):234. PubMed ID: 31895451
[No Abstract] [Full Text] [Related]
11. Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older.
Li D; McCaw ZR; Wei LJ
JAMA Cardiol; 2020 Feb; 5(2):235. PubMed ID: 31895431
[No Abstract] [Full Text] [Related]
12. Letter by Robinson Regarding Articles, "Bringing Back Targets to 'IMPROVE' Atherosclerotic Cardiovascular Disease Outcomes: The Duel for Dual Goals; Are Two Targets Better Than One?" and "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT".
Robinson JG
Circulation; 2016 Mar; 133(13):e461. PubMed ID: 27022048
[No Abstract] [Full Text] [Related]
13. Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older-Reply.
Bach RG; Cannon CP; Blazing MA
JAMA Cardiol; 2020 Feb; 5(2):235-236. PubMed ID: 31895449
[No Abstract] [Full Text] [Related]
14. Response to the Letter Regarding Article, "Bringing Back Targets to 'IMPROVE' Atherosclerotic Cardiovascular Disease Outcomes: The Duel for Dual Goals; Are Two Targets Better Than One?".
Michos ED; Martin SS; Blumenthal RS
Circulation; 2016 Mar; 133(13):e462. PubMed ID: 27022049
[No Abstract] [Full Text] [Related]
15. Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
Bohula EA; Wiviott SD; Giugliano RP; Blazing MA; Park JG; Murphy SA; White JA; Mach F; Van de Werf F; Dalby AJ; White HD; Tershakovec AM; Cannon CP; Braunwald E
Circulation; 2017 Dec; 136(25):2440-2450. PubMed ID: 28972004
[TBL] [Abstract][Full Text] [Related]
16. Applicability of the IMPROVE-IT Trial to Current Patients With Acute Coronary Syndrome: An NCDR Research to Practice Project.
Maddox TM; Tang F; Downs JR; Masoudi FA; Virani SS; Daugherty SL; Rumsfeld JS
JAMA Intern Med; 2017 Jun; 177(6):887-889. PubMed ID: 28437531
[TBL] [Abstract][Full Text] [Related]
17. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White JA; Tershakovec AM; Blazing MA; Braunwald E
Circulation; 2015 Sep; 132(13):1224-33. PubMed ID: 26330412
[TBL] [Abstract][Full Text] [Related]
18. [The IMPROVE-IT trial showed no favorable effects on well-defined and clinically relevant endpoints].
Mascitelli L; Goldstein MR
G Ital Cardiol (Rome); 2015 Dec; 16(12):739. PubMed ID: 26667950
[No Abstract] [Full Text] [Related]
19. [Effect of simvastatin plus inulin in comparison with simvastatin plus ezetimibe on the treatment of mixed dyslipidemia].
Martínez-Abundis E; Barrera-Durán C; González-Ortiz M; Hernández-Salazar E
Gac Med Mex; 2016 Oct; 152(Suppl 2):88-95. PubMed ID: 27792720
[TBL] [Abstract][Full Text] [Related]
20. Effects of simvastatin, ezetimibe and simvastatin/ezetimibe on mitochondrial function and leukocyte/endothelial cell interactions in patients with hypercholesterolemia.
Hernandez-Mijares A; Bañuls C; Rovira-Llopis S; Diaz-Morales N; Escribano-Lopez I; de Pablo C; Alvarez A; Veses S; Rocha M; Victor VM
Atherosclerosis; 2016 Apr; 247():40-7. PubMed ID: 26868507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
